Thanks to normalizing relations between Cuba and the United States, America could get its hands on a promising lung cancer-fighting vaccine that has been available for free to the public in the island nation since 2011.
The vaccine, called Cimavax, doesn't attack tumors directly, Wired reports, and instead targets a tumor-produced protein that circulates in the blood. When that protein is produced, the body responds with a hormone called epidermal growth factor, which can cause cancer. By attacking the protein that spurs the release of epidermal growth factor, Cimavax aims to check the growth and spread of tumors — but doesn’t necessarily shrink them.
Still, the vaccine's growth-inhibiting focus makes it an intriguing preventative medicine option for various types of cancers, and its low cost and lack of side effects paint it as an attractive alternative to chemotherapy. During New York Gov. Andrew Cuomo's visit to Cuba last month, the Roswell Park Cancer Institute in Buffalo, New York, finalized an agreement with Havana's Center of Molecular Immunology to develop the vaccine in the U.S., with trials slated to begin next year. Read more at Wired.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.